Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs.

PloS one - 1 Jan 2012

Bae Young-Ki, Sung Jee Young, Kim Yong-Nyun, Kim Sunshin, Hong Kyeong Man, Kim Heung Tae, Choi Min Sung, Kwon Jae Young, Shim Jaegal

Abstract excerpt

The epidermal growth factor receptor (EGFR) is a well-established target for cancer treatment. EGFR tyrosine kinase (TK) inhibitors, such as gefinitib and erlotinib, have been developed as anti-cancer drugs. Although non-small cell lung carcinoma with an activating EGFR mutation, L858R, responds well to gefinitib and erlotinib, tumors with a doubly mutated EGFR, T790M-L858R, acquire resistance to these drugs. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Butadienes
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Models, Animal

Share to Nitriles

Share to Quinazolines

Share to Transgenes

Share to Tyrphostins

Source

Open in PubMed Open full text

Identifiers

PMID: 22957020
DOI: 10.1371/journal.pone.0042441
PMCID: PMC3434183

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs.PMID 22957020Read ↗

Rab8 and Rabin8-Mediated Tumor Formation by Hyperactivated EGFR Signaling via FGFR Signaling.Semantic proximity Read ↗

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans.Semantic proximity Read ↗

Mutations in the Caenorhabditis elegans let-23 EGFR-like gene define elements important for cell-type specificity and function.Semantic proximity Read ↗

A sequencing-based screening method identifies regulators of EGFR signaling from nonviable mutants in Caenorhabditis elegans.Semantic proximity Read ↗

Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in Caenorhabditis elegans.Semantic proximity Read ↗

C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.Semantic proximity Read ↗

A point mutation in the extracellular domain activates LET-23, the Caenorhabditis elegans epidermal growth factor receptor homolog.Semantic proximity Read ↗

C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype.Semantic proximity Read ↗

An In Vivo EGF Receptor Localization Screen in C. elegans Identifies the Ezrin Homolog ERM-1 as a Temporal Regulator of SignalingSemantic proximity Read ↗

Aucklandia lappa DC. extract enhances gefitinib efficacy in gefitinib-resistance secondary epidermal growth factor receptor mutations.Semantic proximity Read ↗

Functional distinction in oncogenic Ras variant activity in Caenorhabditis elegans.Semantic proximity Read ↗

Multiple functions of let-23, a Caenorhabditis elegans receptor tyrosine kinase gene required for vulval induction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.